Posted by Michael Wonder on 05 Feb 2020
Alector announces FDA fast track designation granted to AL101 for the treatment of patients with frontotemporal dementia
5 February 2020 - Alector today announced that the U.S. FDA has granted fast track designation to AL101 for the treatment of patients with progranulin gene mutations causative of frontotemporal dementia.
AL101, the company’s second product candidate designed to restore progranulin levels in the brain, is currently being evaluated in a Phase 1 trial in healthy volunteers.
